Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694160 | 0.84 | AR (0.46) | HSD11B1SCN9AAR | |
| SCHEMBL3534868 | 0.81 | HSD11B1 (0.44) | HSD11B1CNR2SCN9AARCES1 | |
| SCHEMBL5539576 | 0.81 | — | — | |
| SCHEMBL3532604 | 0.79 | FABP4 (0.36) | SCN9AARPDK2 | |
| SCHEMBL2597833 | 0.78 | HSD11B1 (0.51) | HSD11B1CNR2SCN9AARCES1 | |
| SCHEMBL6067687 | 0.75 | HSD11B1 (0.55) | HSD11B1CNR2SCN9AARCES1 | |
| SCHEMBL28223418 | 0.75 | HSD11B1 (0.49) | HSD11B1CNR2SCN9AARPDK2 | |
| SCHEMBL4004584 | 0.74 | HSD11B1 (0.42) | HSD11B1CNR2SCN9ACES1 | |
| SCHEMBL3996107 | 0.74 | HSD11B1 (0.42) | HSD11B1CNR2SCN9ACES1 | |
| SCHEMBL2753707 | 0.72 | HSD11B1 (0.40) | HSD11B1CNR2SCN9ACES1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070293667-A1 | 4-Amino-quinazolines | MEDERSKI WERNER | 2007-12-20 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20040044204-A1 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044204-A1 | 4-amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | HSD11B1 4738/4885CNR2 258/4885SCN9A 671/4885 |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | HSD11B1 1786/4885CNR2 1088/4885SCN9A 404/4885 |
| US-20070293667-A1 | 4-Amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | HSD11B1 4810/4885CNR2 438/4885SCN9A 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.